COM:IMUX
Immunic
- Stock
locale
United Statesmarket
STOCKSindustry
Biotechnologywebsite
imux.com/ipo date
Apr 17, 2014
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoi...Show More